The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is in focus today after the company reported record Q3 2025 DAYBUE net sales of US$101.1 million, up 11% from a year earlier, and royalty income of A$16.4 million, up 24% year-on-year.
Image source: Getty Images
What did Neuren Pharmaceuticals report?
- Q3 2025 DAYBUE™ (trofinetide) net sales rose 11% to US$101.1 million from Q3 2024, and 5% quarter-on-quarter.
- Royalty income to Neuren was A$16.4 million, up 24% on Q3 2024 and 12% on Q2 2025.
- More than 1,000 patients received DAYBUE shipments in Q3, the first time passing this milestone.
- 74% of new patient prescriptions came from community physicians rather than specialist centres.
- Forecast full-year 2025 US royalty income is A$63–66 million based on updated Acadia sales guidance.
- Named patient supply programs are active across Europe, the Middle East, Israel, and Latin America.
What else do investors need to know?
Acadia Pharmaceuticals, Neuren's US partner, refined its DAYBUE US net sales guidance for 2025 to US$385–400 million. This points to ongoing sales growth and higher royalty flow to Neuren if targets are met.
In the US, penetration remains under 50%, leaving room for further expansion. The majority of new DAYBUE users are coming from community physicians, highlighting broadening demand beyond specialist clinics.
Europe remains a focus, with a regulatory opinion expected in Q1 2026. In Japan, a Phase 3 trial is underway, setting the groundwork for future market entries.
What's next for Neuren Pharmaceuticals?
Looking ahead, Neuren will benefit from growing DAYBUE sales and royalties as market penetration increases, particularly in the US community setting. Key catalysts include the awaited European regulatory opinion and ongoing expansion of named patient supply programs.
Neuren is also progressing NNZ-2591, its second drug candidate, in multiple clinical trials for other rare neurological conditions. Each program has earned "orphan drug" designation in both the US and EU, supporting future therapy development.
Neuren Pharmaceuticals share price snapshot
Neuren Pharmaceuticals share price has risen 47% over the past 12 months, significantly outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 7% over the same period.
